A global eye-care company that makes contact lenses sold under brands like DAILIES, AIR OPTIX, and Precision1, plus surgical equipment and products for cataract and vision-correction procedures, used by eye doctors and patients worldwide. It was founded in 1945 in Fort Worth, Texas, when two pharmacists, Robert Alexander and William Conner, blended sterile eye drops at night in their small pharmacy — and the name Alcon comes from combining the first syllables of their last names. Today it is headquartered in Geneva, Switzerland, after being spun off from Novartis in 2019.
20-F · Fiscal year ended Dec 31, 2025 · SEC filing ↗
Alcon's operating income fell 8% in 2025 as higher R&D, tariffs, and launch costs offset 5% revenue growth.
Alcon's profitability reversed course in 2025 after two years of rapid expansion. rose 5% to $10.4 billion, but fell 8% to $1.16 billion as a 13% increase in R&D spending, $91 million in new tariffs, and product launch investments raised costs faster than sales grew. The company enters 2026 with a larger portfolio after three acquisitions but facing margin pressure from trade policy and a soft cataract market.
Key takeaways
fell 8% to $1.16 billion and narrowed 1.5 points to 11.2%, as a 13% increase in R&D spending to $990 million, $91 million in incremental tariffs, and higher sales and marketing investments for product launches outweighed the benefit of 5% growth.
rose 5% to $10.4 billion, with Vision Care up 6% to $4.6 billion on contact lens price increases and innovation, and Surgical up 4% to $5.8 billion on consumables and equipment growth, while implantables were flat amid soft cataract market conditions.
rose 9% to $2.3 billion, but was constrained by $1.3 billion in investing outflows that included the acquisitions of Aurion, LumiThera, and Cylite.
The company completed a $750 million program during the year and ended 2025 with $1.5 billion in cash and equivalents, down 9% from the prior year.
fell 4% to $980 million, a smaller decline than , as lower tax expenses partially offset the drop in operating earnings.
What changed
The core decline flagged in 2024 persisted in a different form: reported fell 1.5 points to 11.2%, driven not by costs but by a 13% increase in R&D spending, $91 million in tariffs, and launch investments.
Contact lens growth, which was 9% in 2024 and flagged for sustainability, decelerated to 6% in 2025, though the company attributed the gain to the same drivers of price and innovation.
The AR-15512 dry eye candidate, previously flagged for regulatory progress, was commercialized as TRYPTYR and contributed to a 5% increase in ocular health sales.
What to watch
trajectory as the $91 million in 2025 tariffs and the R&D step-up to $990 million annualize, and whether pricing or volume can offset them.
Implantables growth, which was flat in 2025 amid a soft cataract market, to see whether the condition is cyclical or reflects competitive pressure.
Integration and contribution from the Aurion, LumiThera, and Cylite acquisitions, and the planned LENSAR acquisition expected to close in the first half of 2026.
Section summaries
Quantitative and Qualitative Disclosures About Market Risk
The major financing risks faced by Alcon are managed by the Alcon treasury function. For information about the effects of currency and interest rate fluctuations and how we manage currency and interest risk, see "Item 5. Operating and Financial Review and Prospects—5.A. Operatin…
⌄
The major financing risks faced by Alcon are managed by the Alcon treasury function. For information about the effects of currency and interest rate fluctuations and how we manage currency and interest risk, see "Item 5. Operating and Financial Review and Prospects—5.A. Operating Results" and "—5.B. Liquidity and Capital Resources". Please also see the information set forth under Note 17 to the Consolidated Financial Statements.
150
Alcon faces material risks from cybersecurity threats, AI governance gaps, global supply chain disruptions, and evolving regulatory and pricing pressures in key markets like China.
⌄
Capital allocation shifted toward acquisitions: the company deployed $1.3 billion in investing activities for Aurion, LumiThera, and Cylite, while also completing a $750 million program, moving beyond the debt reduction priority noted when fell below $3 billion in 2024.
The multi-year transformation program completed in 2023 did not prevent the 1.5-point contraction in 2025, as new cost pressures from tariffs and R&D more than absorbed the efficiency gains.
generation as the company balances acquisition spending with the completed $750 million program and any new capital allocation priorities.
Cybersecurity breaches and technology failures, including from third-party partners, could disrupt critical operations, compromise data, and cause significant financial and reputational harm.
Rapid, ungoverned adoption of AI tools by associates creates '' risks, potentially exposing sensitive data, undermining regulatory compliance, and increasing vulnerability to AI-enhanced cyberattacks.
Global supply chain disruptions, including dependencies for components like viscoelastics and APIs, have previously caused shortages and could lead to production interruptions and lost sales.
Intensifying pricing pressure and 'Made in China' procurement policies in China, which accounted for 6% of 2025 , threaten margins and market access for the surgical portfolio.
The ongoing of critical systems introduces risks of downtime, data breaches, and non-compliance with privacy regulations, which could disrupt operations and increase costs.
Failure to obtain or maintain regulatory approvals, particularly under the new EU Medical Device Regulation (MDR), could prevent product commercialization and require costly product rationalization.
Alcon is the global leader in eye care, operating Surgical and Vision Care segments with $10.3 billion in 2025 net sales.
⌄
The Surgical business ($5.8B sales) offers implantables, consumables, and equipment for cataract, vitreoretinal, refractive, and glaucoma surgeries, holding the #1 market position.
The Vision Care business ($4.6B sales) comprises contact lenses (daily disposable, reusable, color-enhancing) and ocular health products (dry eye, allergies, glaucoma, lens care).
Alcon serves patients in over 140 countries, with the US representing 45% of , and employs over 25,000 associates globally.
The company invested $990 million in R&D in 2025, focusing on innovations like the UNITY surgical systems, Clareon PanOptix Pro IOL, and TRYPTYR dry eye treatment.
Key competitive strengths include a comprehensive 'one-stop shop' portfolio, a large of surgical equipment driving recurring consumable sales, and strong relationships with eye care professionals.
Strategy focuses on maximizing key product growth, accelerating innovation, expanding into adjacencies like pharmaceuticals, and leveraging infrastructure for margin improvement.
Alcon's 2025 net sales rose 5% to $10.3B, but operating income fell 4% to $1.4B on higher R&D, tariffs, and launch investments.
⌄
Total grew 5% to $10.3B, with Surgical up 4% ($5.8B) and Vision Care up 6% ($4.6B), each benefiting 1% from currency.
Surgical growth was led by consumables (+6%) and equipment (+6%), while implantables were flat amid soft cataract market conditions and competitive pressures.
Vision Care growth was driven by contact lenses (+6%) on price and innovation, and ocular health (+5%) led by dry eye products like Tryptyr and Systane.
declined 4% to $1.4B and fell 1.2pp to 13.2%, pressured by higher R&D (+13%), sales and marketing investments, and $91M in incremental tariffs.
Net rose to $2.3B, but was impacted by $1.3B in investing outflows including acquisitions of Aurion, LumiThera, and Cylite.
The company completed a $750M program and expects to close the LENSAR acquisition in H1 2026, while noting tariff and currency uncertainties ahead.